Clinical Trials
8 trialsNCT00724425 2015-04-15
A Phase 1 Dose Escalation Study of IPI-493
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT01193491 2015-04-15
Dose Escalation of IPI-493 in Hematologic Malignancies
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00096005 2014-02-24
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00019708 2013-12-16
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00098488 2013-06-04
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00103272 2013-06-04
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00354185 2013-05-16
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00319930 2010-03-08
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Biogen
Phase 1 Terminated